Arcadia Biosciences Inc

Arcadia Biosciences Inc(RKDA)の株式分析

$0.167

+0.007 (+3.98%)終値時点

Loading chart…
高値
0.171
始値
0.165
出来高加重平均価格
0.16
出来高
121.01K
時価総額
4.25M
安値
0.154
売買代金
19.87K
EV/EBITDA(TTM)
1.43

Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour.

arcadiabio.com

AI分析 of Arcadia Biosciences Inc (RKDA)

売り

Arcadia Biosciences Inc (RKDA) is not a good buy right now due to its current price of $0.16, a year-to-date change of -92.52%, and a concerning forward P/E ratio of 36.63, indicating potential overvaluation despite the low stock price. The company is facing significant financial challenges, including a recent report of a Q4 GAAP EPS of -$0.97 and a revenue decline of 26.2% year-over-year, which raises serious doubts about its future profitability and growth potential.

アナリスト評価(1)

中立
0 買い
1 中立
0 売り
現在: 0.17
安値
—
平均
—
高値
—

HC Wainwright & Co.

2024-08-21

目標株価

$6

強い買い

HC Wainwright & Co.

2024-05-23

目標株価

$6

強い買い

HC Wainwright & Co.

2024-04-05

目標株価

$10

強い買い

HC Wainwright & Co.

2023-08-28

目標株価

$10

強い買い

HC Wainwright & Co.

2023-07-24

目標株価

$15

強い買い

バリュエーション指標

Arcadia Biosciences Inc(RKDA)の現在の予想PERは36.63で、5年平均は5.54です。

予想PER

大幅な割高
5年平均 P/E
5.54
現在のP/E
36.63
割高
20.96
割安
-9.87

予想EV/EBITDA

割高
5年平均 EV/EBITDA
0.43
現在のEV/EBITDA
1.43
割高
1.19
割安
-0.34

予想PSR

割安
5年平均 P/S
0.85
現在のP/S
0.05
割高
1.43
割安
0.26

Alphio AI による RKDA の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%RKDA

$5.40

シナリオ価格

基

基本

基本 · 50%RKDA

$5.18

シナリオ価格

弱

弱気

弱気 · 25%RKDA

$5.10

シナリオ価格

イベントタイムライン

2026-06-26 (ET)

17:00:00

Arcadia Biosciences Files to Sell 11.92M Shares of Common Stock

2026-06-11 (ET)

21:00:00

Arcadia Biosciences Sells 3,883,496 Shares at $1.03 Each

2026-01-28 (ET)

06:10:00

Arcadia Biosciences Files to Sell 1.67M Shares of Common Stock

2026-01-20 (ET)

06:10:00

Rockwell Medical Sees Q4 Gross Margin Rise to 22%

2026-01-12 (ET)

08:50:00

Arcadia Biosciences Issues Preferred Investment Options, Raises Approximately $2.1M

ニュース

RKDA のよくある質問 — Alphio AI が回答

Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour. It operates in the Consumer Non-Cyclicals sector.

Arcadia Biosciences Inc (RKDA) is not a good buy right now due to its current price of $0.16, a year-to-date change of -92.52%, and a concerning forward P/E ratio of 36.63, indicating potential overvaluation despite the low stock price. The company is facing significant financial challenges, including a recent report of a Q4 GAAP EPS of -$0.97 and a revenue decline of 26.2% year-over-year, which raises serious doubts about its future profitability and growth potential.

1 analysts cover RKDA: 0 rate it Buy, 1 Hold and 0 Sell.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める